NASDAQ:NKTR - Nektar Therapeutics Stock Price, Price Target & More

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Nektar Therapeutics (NASDAQ:NKTR) posted its earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.08. The biopharmaceutical company earned $38.02 million during the quarter, compared to analysts' expectations of $35.59 million. Nektar Therapeutics had a negative return on equity of 202.41% and a negative net margin of 40.07%. Nektar Therapeutics's revenue for the quarter was up 53.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.42) EPS. View Nektar Therapeutics' Earnings History.

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Nektar Therapeutics.

12 Wall Street analysts have issued 12 month price targets for Nektar Therapeutics' shares. Their forecasts range from $20.00 to $125.00. On average, they expect Nektar Therapeutics' share price to reach $81.1818 in the next twelve months. This suggests a possible upside of 69.9% from the stock's current price. View Analyst Ratings for Nektar Therapeutics.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Nektar Therapeutics saw a increase in short interest in the month of June. As of June 15th, there was short interest totalling 16,926,100 shares, an increase of 33.4% from the May 31st total of 12,686,538 shares. Based on an average daily trading volume, of 9,900,153 shares, the days-to-cover ratio is currently 1.7 days. Currently, 10.0% of the company's shares are short sold. View Nektar Therapeutics' Current Options Chain.

Some companies that are related to Nektar Therapeutics include Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and Genmab A/S (GNMSF).

Media headlines about NKTR stock have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nektar Therapeutics earned a daily sentiment score of 0.12 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.14 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Nektar Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.27%), Bank of Montreal Can (0.08%), Franklin Street Advisors Inc. NC (0.03%), Gulf International Bank UK Ltd (0.03%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%) and State of Alaska Department of Revenue (0.03%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.

NKTR stock was sold by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB and Rathbone Brothers plc. Company insiders that have sold Nektar Therapeutics company stock in the last year include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

NKTR stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Scout Investments Inc., Franklin Street Advisors Inc. NC, Gulf International Bank UK Ltd, Fjarde AP Fonden Fourth Swedish National Pension Fund, State of Alaska Department of Revenue, DnB Asset Management AS and Xact Kapitalforvaltning AB. Company insiders that have bought Nektar Therapeutics stock in the last two years include R Scott Greer and Roy A Whitfield. View Insider Buying and Selling for Nektar Therapeutics.

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NKTR stock can currently be purchased for approximately $47.79.

Nektar Therapeutics has a market capitalization of $8.19 billion and generates $30.71 million in revenue each year. The biopharmaceutical company earns $-96,690,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Nektar Therapeutics employs 509 workers across the globe.

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]